NEWS ON THE FIGHT FOR BETTER TREATMENT, A VACCINE, AND A CURE FOR AIDS
Michael Palm HIV Pathogenesis and Prevention Research Project to Strengthen HIV Immunology, Vaccine, & Prevention Research Advocacy
Four-year project to strengthen TAG’s efforts to accelerate search for immune-based HIV therapies, vaccines, microbides, and a cure
NEW YORK, New York, 1 December 2005 – The Treatment Action Group (TAG) announced today on World AIDS Day the establishment of the Michael Palm HIV Pathogenesis and Prevention Research Project. The Project will work to strengthen basic science, immunology, and biomedical HIV prevention research efforts directed at clarifying understanding of how HIV destroys the immune system, how to develop effective immune-based therapy strategies, and how to develop biomedical preventive approaches such as vaccines, microbicides, and treatments to prevent HIV infection pre- and postexposure. The Michael Palm HIV Pathogenesis and Prevention Research Project is supported by a four-year, $1 million grant from the Michael Palm Foundation. HIV is the world's leading infectious cause of illness and death. UNAIDS estimates that over the past year, five million people were infected by HIV and that 3.1 million people died of AIDS.
Towards a Revolution in Tuberculosis (TB) Prevention, Care and Treatment
Statement of Individuals from Communities Affected by Tuberculosis (TB)
23 October 2005 - We are individuals from communities affected by the worldwide pandemic of tuberculosis (TB). We have seen the unnecessary suffering and death that TB causes, amplified by the overlapping HIV/AIDS pandemic. Up to two billion people worldwide are infected with the bacteria which causes TB. Each year, eight million people develop TB disease and two million die from it. Yet TB is preventable, treatable, and curable. The suffering and death it causes are unnecessary and unacceptable.
2005 Pipeline Report
New HIV Drugs, Vaccines, Microbicides, HCV and TB Treatments in Clinical Trials
July 2005 - This overview of the antiretroviral, vaccine, microbicide, immune-based therapy, and anti-HCV and TB drug pipeline (focusing on products that have advanced to clinical testing in humans) reveals the state of research on AIDS and its most common global co-infections in mid-2005. The news is mixed.
2005 Pipeline Report—Part I: Complications
The title not only refers to the multi-side effects that people are dealing with on a regular basis both with and without their meds, but also to the myriad possibilities of what you can take (not counting the drugs out of general use now, nor the two-in-one or the three-in-one formulations, there are 17 drugs to mix and match), what you can't take it with (due to interactions, either within the ARVs themselves or when you are taking non-ARV meds, be they lipid lowerers, antidepressants, OI prophylaxis, or because of access issues), what you try to avoid (due to side effects, previous treatment history), and general treatment fatigue (we are in the ninth year of generalized HAART).
Lactic Acidosis, 2005
The term lactic acidosis describes high levels of lactate in the blood. Lactate is a by-product of the breakdown of sugar in the body. Although lactic acidosis is very rare, people who develop it can become dangerously ill, or even die.
Position Paper on Tipranavir Approval
19 May 2005 - Rob Camp, Antiretoviral Project Director for the Treatment Action Group (TAG), today testified in favor of Food and Drug Administration (FDA) accelerated approval for Boehringer Ingelheim’s Aptivus brand tipranavir, TM a novel anti-HIV protease inhibitor which, when used in combination with Abbott’s NorvirTM brand ritonavir and at least one other active new drug, can be effectively used to treat some strains of HIV which have become resistant to other, more widely used HIV protease inhibitors.